Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 1, Janvier 2013
Page(s) 65 - 73
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013291015
Publié en ligne 25 janvier 2013
  1. Semerano L, Boissier MC. Les anticorps monoclonaux dans les maladies immunes inflammatoires chroniques. Med Sci (Paris) 2009 ; 25 : 1108–1112. [CrossRef] [EDP Sciences] [PubMed]
  2. Sibilia J. Protéine de fusion ou anticorps monoclonal: quel biomédicament choisir dans une maladie inflammatoire ? Med Sci (Paris) 2009 ; 25 : 1033–1038. [CrossRef] [EDP Sciences] [PubMed]
  3. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006 ; 15 : 308–318. [CrossRef] [PubMed]
  4. Mariette X. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases. Joint Bone Spine 2004 ; 71 : 357–360. [CrossRef] [PubMed]
  5. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the french autoimmunity and rituximab registry. Arthritis Rheum 2010 ; 62 : 2458–2466. [CrossRef] [PubMed]
  6. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010 ; 62 : 222–233. [CrossRef] [PubMed]
  7. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012 ; 64 : 1215–1226. [CrossRef] [PubMed]
  8. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum 2010 ; 62 : 1452. [CrossRef]
  9. Wallace DJ, McKay J, Kelley L, et al. Long-term safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus (SLE): 2-year interim data from an open-label re-treatment study. Ann Rheum Dis 2011 ; suppl : AB0885.
  10. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008 ; 67 : 450–457. [CrossRef] [PubMed]
  11. Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010 ; 12 : R204. [CrossRef] [PubMed]
  12. Hikida M, Johmura S, Hashimoto A, et al. Coupling between B cell receptor and phospholipase C-gamma2 is essential for mature B cell development. J Exp Med 2003 ; 198 : 581–589. [CrossRef] [PubMed]
  13. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005 ; 202 : 1363–1374. [CrossRef] [PubMed]
  14. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002 ; 109 : 59–68. [PubMed]
  15. Ramanujam M, Wang X, Huang W, et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004 ; 173 : 3524–3534. [PubMed]
  16. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011 ; 63 : 3918–3930. [CrossRef] [PubMed]
  17. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 ; 377 : 721–731. [CrossRef] [PubMed]
  18. Wallace DJ, Navarra S, Petri M, et al. Safety profile of Belimumab, a B-lymphocyte stimulator specific inhibitor, in phase 2 and 3 clinical trials of patients with active systemic lupus erythematosus. Arthritis Rheum 2011 ; 63 : 578.
  19. Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007 ; 56 : 4142–4150. [CrossRef] [PubMed]
  20. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009 ; 18 : 547–555. [CrossRef] [PubMed]
  21. Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF, corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012 ; 14 : R33. [CrossRef] [PubMed]
  22. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010 ; 62 : 3077–3087. [CrossRef] [PubMed]
  23. Mathian A, Koutouzov S. Interféron-alpha : une cytokine clé dans la physiopathologie du lupus systémique. Rev Med Interne 2008 ; 29 : 696–700. [CrossRef] [PubMed]
  24. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003 ; 197 : 711–723. [CrossRef] [PubMed]
  25. McBride J, Wallace D, Yao Z, et al. Dosedependent modulation of interferon regulated genes with administration of single, repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE. Arthritis Rheum 2009 ; 60 : 2072.
  26. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008 ; 10 : 202. [CrossRef] [PubMed]
  27. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 2012 ; 11 : 321–325. [CrossRef] [PubMed]
  28. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010 ; 62 : 542–552. [CrossRef] [PubMed]
  29. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008 ; 14 : 748–755. [CrossRef] [PubMed]
  30. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011 ; 3 : 73ra19. [CrossRef] [PubMed]
  31. Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010 ; 16 : 701–707. [CrossRef] [PubMed]
  32. Kaveri SV, Mouthon L, Bayry J. Basophils and nephritis in lupus. N Engl J Med 2010 ; 363 : 1080–1082. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.